The ErbB/HER family of receptor tyrosine kinases consists of four receptors that bind a large number of growth factor ligands sharing an epidermal growth factor-(EGF)-like motif. Whereas ErbB-1 binds seven dierent ligands whose prototype is EGF, the three families of neuregulins (NRGs) activate ErbB-3 and/or ErbB-4. Here we characterize a fourth neuregulin, NRG-4, that acts through ErbB-4. The predicted pro-NRG-4 is a transmembrane protein carrying a unique EGF-like motif and a short cytoplasmic domain. A synthetic peptide encompassing the full-length EGF-like domain can induce growth of interleukin-dependent cells ectopically expressing ErbB-4, but not cells expressing the other three ErbB proteins or their combinations. Consistent with speci®city to ErbB-4, NRG-4 can displace an ErbB-4-bound NRG-1 and can activate signaling downstream of this receptor. Expression of NRG-4 mRNA was detected in the adult pancreas and weakly in muscle; other tissues displayed no detectable NRG-4 mRNA. The primary structure and the pattern of expression of NRG-4, together with the strict speci®city of this growth factor to ErbB-4, suggest a physiological role distinct from that of the known ErbB ligands.
Introduction
Cell-to-cell signaling is an essential feature of multicellular organisms, playing important roles in both the unfolding of developmental diversi®cation as well as mediating the homeostasis of vastly dierent cell types. A large number of tyrosine kinase growth factor receptors play key roles in this process. Type-1 tyrosine kinase receptors, also known as ErbB/HER proteins, comprise one of the better-characterized families of growth factor receptors, of which the epidermal growth factor receptor (ErbB-1) is the prototype (reviewed in Burden and . The ErbB family constitutes four known receptors which dimerize upon ligand stimulation, transducing their signals by subsequent autophosphorylation catalyzed by an intrinsic cytoplasmic tyrosine kinase, and recruiting downstream signaling cascades.
The ErbBs are activated by a large number of ligands. Depending upon the activating ligand, most homodimeric and heterodimeric ErbB combinations can be stabilized upon ligand binding , thus allowing a complex, diverse downstream signaling network to arise from these four receptors. The choice of dimerization partners for the dierent ErbBs, however, is not arbitrary. Spatial and temporal expression of the dierent ErbBs do not always overlap in vivo, thus narrowing the spectrum of possible receptor combinations that an expressed ligand can activate for a given cell type (Erickson et al., 1997; Gassmann et al., 1995; Lee et al., 1995; PinkasKramarski et al., 1997; Riethmacher et al., 1997) . Furthermore, a hierarchical preference for signaling through dierent ErbB receptor complexes takes place in a ligand-dependant manner. Of these, ErbB-2-containing combinations are often the most potent, exerting prolonged signaling through a number of ligands, likely due to an ErbB-2-mediated deceleration of ligand dissociation Tzahar et al., 1996; Wang et al., 1998) . In contrast to possible homodimer formation of ErbB-1 and ErbB-4, for ErbB-2, which has no known direct ligand, and for ErbB-3, which lacks an intrinsic tyrosine kinase activity (Guy et al., 1994) , homodimers either do not form or are inactive. Heterodimeric ErbB complexes are arguably of importance in vivo. For example, mice defective in genes encoding either NRG-1, or the receptors ErbB-2 or ErbB-4, all result in identical failure of trabeculae formation in the embryonic heart, consistent with the notion that trabeculation requires activation of ErbB-2/ErbB-4 heterodimers by NRG-1 (Gassmann et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995) .
At the biochemical level, the known ErbB ligands fall into several categories (Riese et al., 1996b) . One category, the ErbB-1 ligands, includes EGF, transforming growth factor a (TGFa), epiregulin, amphiregulin, betacellulin and the heparin-binding EGF (HB-EGF) (Higashiyama et al., 1991; Marquardt et al., 1984; Shing et al., 1993; Shoyab et al., 1989; Toyoda et al., 1995) . To dierent extents, these ErbB-1 binding ligands can also activate other receptors of the ErbB family, and hence may mediate distinct signaling outputs for a given cell type (reviewed in Tzahar and Yarden, 1998) . Another category of ErbB ligands consists of the Neuregulin (NRG) family. NRG-1 (also named Neu dierentiation factor (NDF), heregulin, glial growth factor, and acetylcholine receptor inducing activity) was ®rst identi®ed by its ability to indirectly phosphorylate ErbB-2 (Holmes et al., 1992; Peles et al., 1992; Wen et al., 1992) . Subsequently, NRG-1 was found to directly bind ErbB-3 and ErbB-4 and to sequester ErbB-2 by receptor dimerization (Peles et al., 1993; Plowman et al., 1993; Sliwkowski et al., 1994; Tzahar et al., 1994) . Multiple isoforms of NRG-1 exist which amongst other roles, permit heterogeneous binding anities to dierent ErbB complexes (Tzahar et al., 1994) . The NRG family now includes also two isoforms of NRG-2 (Bus®eld et al., 1997; Carraway et al., 1997; Chang et al., 1997; Higashiyama et al., 1997) , of which the alpha isoform is a pan-ErbB ligand , and NRG-3, a ligand of ErbB-4 (Zhang et al., 1997) . The multiplicity of genes encoding ErbB-1 ligands, contrasting with the small number of known genes encoding ligands for ErbB-3 or ErbB-4 (namely: NRGs), led us to believe in the existence of additional NRG genes in the genome of mammals. Here we report on a fourth neuregulin, denoted NRG-4, which acts through the ErbB-4 receptor tyrosine kinase. In addition to its novel structure, this growth factor displays a pattern of expression dierent from other EGF-like molecules.
Results

Identi®cation of a candidate novel ErbB ligand
With the assumption that there may still exist novel ErbB-speci®c ligands we decided to search for new family members by homology. The recent explosion of DNA sequencing data added to DNA databases, largely resultant from the Human Genome Project initiative, oers scanning of these data for novel transcripts coding ligands with homology to the ErbB-3-and ErbB-4-speci®c ligand, NRG-1 (NDF). The motif CX 7 CXNGGXCX 13 CXCX 3 YXGXRC, conserved in most isoforms of NRG-1, was used to scan available new DNA sequences. An expressed sequence tag (EST) clone originating from a mouse liver cDNA library (accession number AA238077) was identi®ed, its sequence encoding an EGF-like domain sharing 32% identity with the NRG-1b isoform . This clone was obtained and fully sequenced, its presumed translation product encoding a protein of 115 amino acids (Figure 1a ). Hydropathy analysis using the Kyte-Doolittle algorithm (Kyte and Doolittle, 1982) supports the existence of a transmembrane domain (Figure 1b ) characteristic to most NRG isoforms (Marchionni et al., 1993; Wen et al., 1994) . Conspicuously, this protein sequence lacks a hydrophobic amino-terminal stretch, commonly found in signal peptide motifs, important in sequestering proteins to traverse the plasma membrane. Most isoforms of NRG-1 also lack consensus signal peptide sequences, but they carry an apolar N-terminal sequence thought to allow transmembrane orientation of the precursor molecule. The predicted extracellular domain of the precursor protein includes the EGF-like domain, whose primary structure displays the entire structural motifs characteristic to the EGF/NRG family ( Figure 1c) . The putative cytoplasmic domain of the precursor protein is relatively short and contains one potential site for N-glycosylation. Two additional sites are located at the probable ectodomain.
Alignment of the EGF-like domains of all known ErbB-speci®c ligands of mammalian origin indicated that the novel transcript encodes a new member of this family (Figure 1c) . Its characteristic six extracellular cysteine residues and their conserved spacing predict the existence of the three disul®de bridges, denoted as A, B and C, that are the landmark of all EGF-like peptides. Besides the six conserved cysteine residues, the new EGF-like domain shares very high homology with other members of the NRG family, including a glycine at position 21 (Gly-21), Gly-42 and Arg-44, along with many semi-conserved residues. Of note, the expected B loop of the new protein, like the loops of EGF and NRG-2, is shorter by three residues. Except for the EGF-like domain and the transmembrane topology of the novel predicted protein, it shares no Tissue-speci®c expression of the novel transcript
Northern blot analysis of mRNA isolated from dierent human adult tissues revealed moderate expression of the novel transcript in skeletal muscle and high levels in the pancreas (Figure 2 ). Other tissues, including brain and placenta, two rich sources of many dierent growth factors, displayed very low, if any, expression. Three discernible molecular weight species (0.8, 1.8 and 3.0 kilobases) were detectable in pancreas and in muscle, indicating the existence of several mRNA isoforms, the smallest band consistent in size with the clone described in this study.
The EGF-like domain of NRG-4 stimulates proliferation of ErbB-4-expressing cells
To test the prediction that the novel transcript encodes an ErbB-speci®c ligand, we synthesized the corresponding full-length EGF-like domain (residues 4 ± 50, Figure  1a ), denatured and refolded the synthetic peptide to allow proper disul®de bridging. This method has been used before to synthesize functionally active derivatives of other EGF-like growth factors (Barbacci et al., 1995; Lin et al., 1988; Shelly et al., 1998) . Previously we have established a series of derivatives of the 32D cell line engineered to express dierent ErbB receptors or their combinations (Pinkas-Kramarski et al., 1996; Shelly et al., 1998) . The myeloid 32D parental cells require cytokine stimulation, such as interleukin 3 (IL3) for their growth, and were chosen because they lack endogenous ErbB expression. Signaling through dierent ErbB-receptors can replace the IL3-dependent mitogenicity and survival for these cell lines, and hence this system provides a sensitive means to detect ligandinduced growth signals, which are conveniently measured as a function of cellular metabolic activity by using the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl] tetrazolium bromide (MTT) assay (Mosman, 1983) . Cells singly expressing ErbB-1, ErbB-2 or ErbB-3 (denoted D1, D2 or D3, respectively) did not respond to the synthetic novel peptide in a 24-h dose-response assay, although responses to EGF (D1 cells), an ErbB-2-stimulatory monoclonal antibody (D2 cells, ), or IL-3 (D3 cells) were retained ( Figure 3a , and data not shown). The latter cell line is not responsive to NRGs due to the defective kinase of ErbB-3. However, ErbB-4 expressing cells (D4), exhibited a modest dose-dependent mitogenic response in comparison to its counterpart NRG-1b control. Because dierent heterodimeric complexes of ErbB proteins can diversify and enhance signaling by EGF-like ligands (Cohen et al., 1996; Pinkas-Kramarski et al., 1996; Riese et al., 1995) , cells co-expressing two ErbB proteins (for example D12 cells co-express ErbB-1 and ErbB-2) were also tested for NRG-4-induced mitogenicity. Of the tested combinations, namely: D12, D13, D23 and D24 cells, a cell line expressing a combination of ErbB-4 with ErbB-2 (D24 cells) was the only line that responded mitogenically to the novel peptide ( Figure  3a) . Notably, co-overexpression of ErbB-1 and ErbB-2 resulted in a relatively high basal proliferation activity, but these cells still responded to EGF ( Figure 3b , and data not shown). Additionally, in cells co-overexpressing ErbB-2 and ErbB-4, NRG-1 and the novel ligand were almost equipotent (compare D4 and D24 panels in Figure 3a ), indicating that ErbB-2 can enhance the mitogenic eect of the novel ligand, as it does for other ErbB ligands (Graus-Porta et al., 1995; Karunagaran et al., 1996; Wang et al., 1998) .
A long-term cell survival assay con®rmed the ability of the novel growth factor to stimulate ErbB-4. This assay examined the ability of added growth factors to sustain survival of certain 32D derivatives in the absence of IL-3. As in the dose-response experiments, the novel synthetic peptide only stimulated the survival of the two ErbB-4-expressing cell lines we examined, namely D4 and D24 cells (Figure 3b ). Also similar to the short-term dose response assay, stimulation of D24 cells was more robust, and akin to the NRG-1-treated controls than was the response of D4 cells. These data indicate that the novel growth factor can exert a weak proliferative signal through ErbB-4 alone, but coexpression of ErbB-2 with ErbB-4 allows a superior mitogenic response, as it does in the case of NRG-1 . On the basis of the ability of the novel synthetic peptide to mediate a biological eect through one of the neuregulin receptors we named it neuregulin-4 (NRG-4).
NRG-4 recognizes and activates ErbB-4
To elucidate the molecular interactions pertaining to NRG-4 signaling, several dierent approaches were employed to test speci®c binding of this growth factor to the four ErbB proteins. In the ®rst assay, binding studies in a cell-free system were performed with recombinant soluble forms of all four ErbB proteins. The soluble proteins, denoted IgB-1 through -4, consist of a dimeric fusion between the extracellular domain of the corresponding ErbB and the Fc portion of a Figure 2 Northern blot analysis of NRG-4 expression in human tissues. Poly(A)-containing RNA from the indicated human tissues (2 mg per lane) was analysed using a nitrocellulose ®lter purchased from Clontech (San Diego, CA, USA). The blot was hybridized with a full-length NRG-4 cDNA probe radiolabeled using the Klenow fragment of DNA polymerase I and random hexamers as primers. Following autoradiography, the ®lter was stripped of radioactivity and re-probed sequentially with pancreas and muscle markers, alpha-amylase-2 and beta-actin, respectively. Molecular weights of marker molecules are indicated in kilobases (kb). Note that beta-actin probe also hybridized with a larger molecular weight isoform present in heart and in skeletal muscle Novel ErbB-4 ligand D Harari et al human immunoglobulin G . NRG-4, EGF and NRG-1b were radiolabeled with 125 I, incubated with the soluble receptors, and then irreversibly bound to the IgBs using the BS 3 covalent crosslinking reagent. As expected for the controls, a strong signal was detected for EGF binding to IgB-1 in contrast to NRG-1b, which bound strongly to IgB-3 and IgB-4, but no ligand bound to IgB-2 (Figure 4a) . In comparison to NRG-1, 125 I-NRG-4 bound to the soluble form of ErbB-4 (IgB-4) only weakly, with low or no binding to the other IgB proteins (Figure 4a ). To con®rm speci®city of the covalent crosslinking assay we co-incubated unlabeled NRG-4, at 100-fold molar excess, together with the radioactive ligand and observed ecient displacement from IgB-4 (lower panel of Figure 4a ). Thus, consistent with the ability of NRG-4 to induce growth and survival of ErbB-4-expressing cells, but not cells singly expressing the other three ErbBs, this ligand recognized only ErbB-4 (IgB4) in solution.
To test the prediction that NRG-4 can recognize a surface-expressed ErbB-4, but no other membranebound ErbB protein, we used a Chinese hamster ovary (CHO) cell line. These cells express low amounts of ErbB-2, but no other ErbB receptor, and accordingly did not bind NRG-4 or any other neuregulin , and data not shown). CHO cells were transfected with plasmid vectors directing expression of ErbB-4, or co-transfected with an ErbB-4 plasmid together with vectors expressing one of the three other ErbB proteins. Two days later, cells were incubated with 125 I-NRG-4, or with a radiolabeled NRG-1 as control, and subsequently the formed ligand-receptor complexes were stabilized by using a covalent crosslinking reagent. Immunoprecipitation of the expressed ErbB proteins allowed analysis of the covalently held complexes. Expression of ErbB-4 alone conferred to CHO cells the ability to form complexes with NRG-4, as well as with NRG-1 (Figure 4b , and data not shown). In line with the lower mitogenic activity of NRG-4, the covalent crosslinking signal obtained with this ligand was weaker than that observed with a radioactive NRG-1. Nevertheless, both monomers and dimers of ErbB-4 were formed by the two ligands (detection of NRG-4-containing dimers required long ®lm exposures). Co-expression of ErbB-1 or ErbB-3 did not signi®cantly aect the radioactive signals, but in the case of ErbB-2 an enhancement eect was observed with NRG-1. The ability of anti-ErbB-1 and anti-ErbB-2 antibodies to precipitate NRG-4-labeled monomeric and dimeric receptor species (Figure 4b ) is probably due to co-immunoprecipitation of ErbB-4 and it indicates the existence of NRG-4-promoted heterodimers with ErbB-1 and ErbB-2. Interestingly, ErbB-3 largely escaped heterodimerization with ErbB-4 following binding of NRG-1 or NRG-4.
Taken together, the biological eects of NRG-4 and its complex formation with ErbB-4 implied not only speci®city of recognition, but also weaker interaction relative to NRG-1. To quantify the interaction, we performed ligand displacement analysis on ErbB-4-expressing CHO cells. The ability of unlabeled NRG-4 to displace surface-bound radiolabeled NRG-1-b was compared with that of unlabeled NRG-1. The results of this experiment indicated an approximately eightfold lower binding anity of NRG-4 to ErbB-4 (Figure 4c ). While NRG-1 bound with an apparent anity that lies in the low nM range, NRG-4 displayed an apparent approximate Kd of 20 nM. In conclusion, NRG-4 speci®cally binds to ErbB-4 with an anity that is lower than that of NRG-1b. Because we previously reported that relative to NRG-1b the alpha isoform displays a 5 ± 8-fold lower anity to both ErbB-3 and ErbB-4 (Tzahar et al., 1994) , it is conceivable that NRG-4 and NRG-1a bind to ErbB-4 with similar anities.
Evidently, NRG-4 binds to ErbB-4 and mediates cell proliferation through activation of this receptor. Because other ErbB ligands stimulate cell growth via tyrosine phosphorylation of their respective receptors and activation of the intervening mitogen-activated protein kinase (MAPK) cascade, we tested these two signaling steps in NRG-4-responsive myeloid cells expressing ErbB-4 (D4 and D24 cell lines). Cells were stimulated with 100 ng/ml of activating ligand for 5 min, followed by lysis and analysis by immunoblotting. NRG-4 stimulated phosphorylation of the 180-kDa ErbB receptors in D4 and in D24 cells with an accompanying activation of MAP-kinase (Erk-1 and Erk-2) also detected ( Figure 5 ). In contrast to these two cell lines, and consistent with the growth and binding assays, NRG-4 at doses as high as 1 mg/ml, did not stimulate the other 32D cell lines (D1, D2, D3, D12, D13 and D23 cells, data not shown). These results further support the conclusion that NRG-4 is a bona ®de ligand of the ErbB receptor family that selectively interacts with receptor complexes containing ErbB-4.
Discussion
In this paper we identify and present the initial characterization of NRG-4, a new cognate ligand of the EGF/NRG family. Aside from NRG-4 possessing a neuregulin-like EGF domain (Figure 1c) , it shares very little other sequence homology to the known NRGs, particularly in the vicinity of the transmembrane domain, a region where the other three NRGs exhibit high primary sequence homology. However, the presumed precursor form of NRG-4 shares several structural characteristics with other mammalian ErbB ligands (reviewed in Massague and Pandiella (1993) ), including a transmembrane topology, a juxtamembrane location of the EGF-like domain, and a putative proteolytic cleavage site located at a serine-rich region C-terminally to the EGF-like domain. This region may serve as a site of O-glycosylation, in addition to two potential sites of N-glycosylation located in the presumed ectodomain of NRG-4. Like other NRGs, but unlike most ErbB-1-speci®c ligands, NRG-4 lacks an N-terminally located hydrophobic signal peptide. However, the absence of a characteristic sequence may not exclude the possibility that NRG-4 acts as a secreted growth factor, because other signal peptideless growth factors can be secreted or released from producer cells through alternative secretory mechanisms or upon cell lysis. NRG-4 presents a rather unique case as it also lacks an apolar stretch of amino acids that usually replaces a signal peptide (e.g., in NRG-1).
In fact, the presumed ectodomain of NRG-4 is the shortest among NRG/EGF family members. In addition, unlike other NRGs, which contain a variety of structural motifs, such as an immunoglobulin-like domain, a cysteine-rich region, or a mucin-like domain, NRG-4 contains no recognizable structural motif other than the EGF-like domain.
That the EGF-like domain of NRG-4 functions as a receptor-binding moiety is indicated by our in vitro studies with engineered cell lines and also with breast cancer cells naturally expressing all four ErbB proteins (Figures 3 ± 5, and data not shown) . The EGF-like domain of NRG-4 exhibits restricted binding specificity, it directly binds to ErbB-4, but not to ErbB-1, ErbB-2 or ErbB-3. A similar selective binding to ErbB-4 has also been reported for NRG-3 (Zhang et al., 1997) and may indicate that during development and in the adult, ligands with restricted ErbB speci®cities may play important roles. It is interesting to note that NRG-3 is the EGF-like ligand closest to NRG-4 (42% sequence identity in the EGF-like domain). Also relevant is the emerging wider repertoire of ErbB-4-speci®c ligands, as compared with growth factors that bind to ErbB-3. In addition to NRG-1, NRG-2, and NRG-3, ErbB-4 also binds to betacellulin (Riese et al., 1996a) , epiregulin and HB-EGF (Elenius et al., 1997) . Moreover, at high ligand concentrations, or in the presence of a co-expressed ErbB-2, ErbB-4 also binds EGF and TGFa Wang et al., 1998) . The broader speci®city of ErbB-4 was re¯ected also in mutagenesis experiments: more NRG-1 mutants displayed greater anity loss for ErbB-3 compared with ErbB-4 (Jones et al., 1998) .
Besides speci®city to ErbB-4, NRG-3 and NRG-4 share relatively low anity to this receptor compared with NRG-1 (Figure 4 and Zhang et al., 1997) . Several other ligands, such as epiregulin and the alpha isoform of NRG-1 (Tzahar et al., 1994) , also display relatively low anity to ErbB-4. These observations may suggest the existence of additional, yet undiscovered ErbB proteins, serving as high anity receptors for these low anity ligands. Alternatively, low anity ligands may have a dierent biological function than high anity growth factors, as they can escape the common rapid endocytic clearance from the extracellular space (Reddy et al., 1996; Shelly et al., 1998) . Alternatively, the ligand-less co-receptor of ErbB-4, namely ErbB-2 , may be more eective in the case of low anity ligands, such as NRG-3 and NRG-4, thus oering a mechanism for ®ne-tuning of ErbB signaling. The interaction of ErbB ligands with ErbB-2 appears to involve direct binding to an ErbB-2 promiscuous binding site Tzahar et al., 1997) . According to this model, all EGF-like growth factors are bivalent ligands, that dier in their binding speci®city to speci®c pairs of ErbB receptors (Tzahar et al., 1997) . This hypothesis may explain the multiplicity of ErbB ligands in terms of their dierential ability to stabilize homo-and heterodimeric ErbB proteins. When applied to NRG-4, the bivalence model predicts that this ligand may dier from other ErbB-4-speci®c ligands, including NRG-3, in the ability to recruit heterodimer partners to ErbB-4. Consistent with this model, we demonstrate that when co-expressed with ErbB-4, NRG-4 can recruit Figure 5 Tyrosine phosphorylation and MAPK activation by NRG-4. Derivatives of 32D cells expressing ErbB-4, either alone (D4 cells) or in combination with ErbB-2 (D24 cells) were incubated for 5 min at 378C with either NRG-4 or NRG-1b (each at 100 ng/ml). Whole cell extracts were then prepared, resolved by gel electrophoresis, and transferred to a nitrocellulose ®lter. The upper portion of the ®lter was immunoblotted with antibodies to phosphotyrosine (P-Tyr, the 150 ± 200 kDa region is shown) or an antibody directed at the activated doubly phosphorylated form of the MAPK (Erk1 and Erk2, the 40 ± 50 kDa region is shown). Antibodies were incubated with a secondary reagent coupled to horseradish peroxidase, allowing subsequent detection by chemiluminescence both ErbB-1 and ErbB-2 into heterodimers ( Figure  4b ). These NRG-4-induced heterodimeric complexes may be of physiological importance, as indicated in proliferation assays: NRG-4 weakly stimulated the growth of myeloid cells engineered to express ErbB-4 alone (D4 cells). In contrast, this response was signi®cantly enhanced upon ErbB-2 co-expression (D24 cells, Figure 3 ) when compared to that of the internal NRG-1 control. This ®nding may indicate that under some physiological conditions, the expression of ErbB-4 alone may be insucient to elicit a biological response to NRG-4, requiring a co-receptor such as ErbB-2 to transduce its signal. This scenario has a precedence in the case of NRG-1: in vitro experiments showed clear enhancement of an ErbB-4-mediated mitogenic eect by a co-expressed ErbB-2 , and gene-targeting in mice indicated that ErbB-2 is essential for cardiac trabeculation that is mediated by NRG-1 and ErbB-4 (Lee et al., 1995) .
With the exception of EGF, which is found in high concentrations in body¯uids such as milk, urine and saliva (Carpenter and Cohen, 1979; Gregory et al., 1979) , all of the EGF/NRG family members are thought to act as short-range ligands aecting only neighboring cells through paracrine or autocrine loops (reviewed in Ben-Baruch et al., 1998) . Consistent with short-range ligand-receptor interactions, NRG-3 is expressed primarily in the central nervous system, along with its only known receptor, ErbB-4 (Plowman et al., 1993; Zhang et al., 1997) . However, ErbB-4 is expressed also in muscle, heart, pancreas, salivary gland and lung (Gassmann et al., 1995; PinkasKramarski et al., 1997; Plowman et al., 1993) . Our Northern blot analysis (Figure 2 ) demonstrated that in the adult, two of these ErbB-4-positive tissues, pancreas and muscle, express three molecular weight species of NRG-4. Likewise, multiple mRNA species of NRG-1 and NRG-2 were reported (Chan et al., 1995; Wen et al., 1992) . Whether or not the multiplicity of NRG-4 mRNAs is related to the existence of many isoforms of NRG-1 and NRG-2 (Bus®eld et al., 1997; Carraway et al., 1997; Chang et al., 1997; Marchionni et al., 1993; Wen et al., 1994) is currently unknown.
In summary we describe here the ®rst characterization of NRG-4, a novel member of the ErbB ligand family, whose structure, expression pattern and restrained receptor-binding properties suggest a unique physiological role. Gene-targeting and in vitro studies with recombinant NRG-4 may resolve the presumed distinct biological role of this growth factor and its relationship to other EGF/NRG family ligands.
Materials and methods
Materials
EGF (human, recombinant) was purchased from Boehringer Mannheim. Recombinant human NDFb1 177 ± 246 (NRG1-b1) was obtained from Amgen (Thousand Oaks, CA, USA). Iodogen and bis(sulfosuccinimidyl) suberate (BS 3 ) were from Pierce. Monoclonal antibodies (mAbs) to ErbB proteins Klapper et al., 1997) were used for immunoprecipitation. The composition of buered solutions was described (Tzahar et al., 1994) . Recombinant soluble extracellular domains of the four ErbB proteins (denoted IgB-1 through -4) , in the form of fusion proteins containing the Fc portion of human immunoglobulin G (IgG) were harvested from serum-free conditioned media of transfected HEK-293 human embryonic kidney cells. The PY20 antibody was purchased from Santa Cruz Biotechnology. A mAb to the active form of the MAP kinase (Yung et al., 1997) was a gift from R Seger (Weizmann Institute).
Peptide synthesis
The EGF-like domain of NRG-4 (residues 4 ± 50) was synthesized on an Applied Biosystems (ABI) 430A peptide synthesizer using standard tert-butyloxycarbonyl (t-Boc) chemistry protocols as described (Barbacci et al., 1995) . Acetic anhydride capping was employed after each activated ester coupling. The peptide was assembled on phenylacetamidomethyl polystyrene resin using standard side chain protection, except for the use of t-Boc-Glu(O-cyclohexyl) and t-Boc-Asp(O-cyclohexyl). The peptide was deprotected using the`Low-High' hydro¯uoric acid (HF) method (Tam et al., 1983) . The crude HF product was puri®ed by reverse phase HPLC (C-18 Vydac, 226250 mm), diluted without drying into folding buer (1 M urea, 100 mM Tris, pH 8.0, 1.5 mM oxidized glutathione, 0.75 mM reduced glutathione, 10 mM methionine), and stirred for 48 h at 48C. The folded, fully oxidized peptide was puri®ed from the folding mixture by reverse phase HPLC, and characterized by electrospray mass spectroscopy. A single HPLC peak with an averaged molecular mass (Mr) of 5371.50 was displayed by the reduced peptide prior to folding. This mass is in agreement with the theoretical Mr (5371.20). The folded and oxidized peptide displayed a slightly lower averaged molecular mass of 5366.88.
Database searches
EST databases were scanned for homology to the EGF-like domain of NRG-1b (NDF-b) by Blast and Smith-Waterman algorithms (Samuel and Altschul, 1990; Smith and Waterman, 1981 ) using both a Unix-interfaced GCG server and a Bioaccelerator device (Compugen, Israel).
Northern blot
A Northern blot ®lter was purchased from Clontech (MTN Blot #7760-1), each lane containing approximately 2 mg of poly(A) + puri®ed mRNA from healthy human tissues and run on a denaturing 1.2% formaldehyde/agarose gel. Hybridization to cDNA probes to mouse NRG-4 and human b-actin were performed with`ExpressHyb' (Clontech) using the protocol provided by the manufacturer. Probing with a human amylase cDNA probe was performed by standard techniques. After each hybridization, blots were washed at room temperature for 40 min with several changes of low stringency wash solution (26SSC, 0.05% SDS) and then with at least two changes of high stringency buer (0.16SSC, 0.1% SDS) at 508C for 40 min.
Lysate preparation for Western blot analyses
For receptor activation studies, derivatives of the 32D cell line were resuspended in phosphate-buered solution (PBS) and incubated at 228C for 15 min before adding growth factors and incubating for 5 min at 378C. Cells were then pelleted and lysed in ice cold solubilization buer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Noidet-P-40, 0.5% Nadeoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1.5 mM EDTA, 1.5 mM MgCl 2 , 2 mM Na-orthovanadate, 1 mM phenylmethylsulfonyl¯uoride (PMSF), 10 mg/ml aprotinin and 10 mg/ml leupeptin) and left on ice for 15 min. The whole cell extract was then cleared by centrifugation (12 000 g for 10 min at 48C), immediately boiled in reducing gel sample buer, and resolved by 10% SDS ± PAGE before being 
Radiolabeling of ligands, covalent crosslinking and ligand displacement analyses
Growth factors were labeled with Iodogen (Pierce) as described (Karunagaran et al., 1995) . Chemical crosslinking to Chinese hamster ovary (CHO) cells engineered to express dierent ErbB combinations have been performed essentially as described . Brie¯y, radiolabeled ligands (at 100 ng/ml) were incubated for 2 h with cell monolayers at 48C. The chemical crosslinking agent BS 3 (1 mM) was then added and the cells were further incubated for 45 min at 228C. Mouse antibodies were ®rst coupled to rabbit anti-mouse IgG and to protein A-Sepharose beads, and then they were incubated with cell extracts for 2 h at 48C. Immunoprecipitated complexes were then washed three times with ice-cold SBN buer (1% NP-40; 150 mM NaCl; 10% Glycerol; 1 mM EGTA, in 50 mM Tris-HCl, pH 7.4; 1 ml per wash) prior to heating (5 min at 958C) in gel sample buer, resolution by gel electrophoresis, transfer to nitrocellulose and autoradiography. For crosslinking with IgBs, after co-incubation of IgB-containing conditioned media with radiolabeled ligands, complexes were immunoprecipitated directly with Sepharose-protein A beads. For ligand displacement analyses, cell monolayers were washed once with binding buer, and then incubated for 2 h at 48C with radiolabeled NRG-1b (5 ng/ml) and various concentrations of unlabeled ligands, as indicated. Non-speci®c binding was determined in the presence of a 100-fold molar excess of the unlabeled ligand. Cells were then washed, lysed in a solution containing 0.1 M NaOH and 0.1% SDS, and radioactivity determined by use of a gamma counter.
Cell proliferation assays
The establishment of a series of interleukin 3-(IL-3-) dependent 32D myeloid cells expressing all combinations of ErbB proteins has been described (Alimandi et al., 1997; Pinkas-Kramarski et al., 1996; Shelly et al., 1998) . Cells were maintained in RPMI medium with 10% fetal bovine serum (FBS) and dilute IL3-containing conditioned medium. Prior to proliferation assays, cells were washed three times in RPMI/FBS and plated (5610 5 cells/ml; 0.1 ml/well) into 96-well¯at-bottomed plates with the indicated ligand concentrations or with IL-3 (1 : 1000 dilution of conditioned medium). Cell survival was determined 24 h later, or after the indicated time intervals, by MTT assay, as previously described (Mosman, 1983) . MTT (0.05 mg/ml) was incubated with the analysed cells for 2 h at 378C. Living cells can transform the tetrazolium ring into dark blue formazan crystals, that can be quanti®ed by reading the optical density at 540 ± 630 nm after lysis of the cells with acidic isopropanol.
